伊立替康诱导结直肠癌肝转移患者脂肪性肝炎的研究进展

Research progress in irinotecan induced steatohepatitis in patients with colorectal liver metastases

伊立替康(CPT-11)是结直肠癌肝转移(colorectal liver metastases,CRLM)的一线化疗药物,在消化道肿瘤的治疗中发挥着重要作用。但CPT-11在治疗CRLM时存在一定的肝毒性,会诱发脂肪性肝炎,从而增加CRLM患者在肝切除术后肝肿瘤的复发率、各种术后并发症的发病率和死亡率,不利于疾病的治疗。该文通过查阅国内外相关文献,对CPT-11诱导的脂肪性肝炎的危害、高危因素、潜在机制、以及药物干预的研究进展进行综述,以期为该药在临床的安全合理应用提供参考。

Irinotecan(CPT-11)is a first-line chemotherapy agent for colorectal liver metastases(CRLM)and plays an important role in the chemotherapy of gastrointestinal system cancers.However,CPT-11 has certain hepatotoxicity,which can induce steatohepatitis,thereby increasing the recurrence rate of liver tumor,postoperative complications morbidity and mortality in patients with CRLM after hepatectomy,which is not conducive to the treatment of the disease.By referring to domestic and foreign literature,this paper reviewed the research progress in harm,high risk factors,potential mechanisms and pharmacological interventions of CPT-11-induced steatohepatitis,so as to provide reference for safe and rational use of CPT-11.